Boston Scientific Corporation vs Kaltura Inc — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $71.46B), while Kaltura Inc trades at $1.64 (market cap $250.18M). The key difference: Boston Scientific Corporation is far larger — about 285.6× Kaltura Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | KLTR | |
|---|---|---|
Market Cap | $71.46B | $250.18M |
Sector | Health | Technology |
52-Week High | $108.14 | $1.89 |
52-Week Low | $42.63 | $1.08 |
Enterprise Value | $83.55B | $262.40M |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Kaltura (KLTR) trades at $1.75, up 1.74% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue is stable around $181M, but the company remains unprofitable with a net margin of -6.92%. Positive cash flow from operations and industry recognitions for AI and video platforms highlight growth potential, though high debt and insider selling pose concerns.
The outlook is mixed: analyst consensus leans buy (44% buy ratings) on AI innovation and cash flow improvements, but risks include persistent losses, elevated valuation ratios, and competitive pressures. Investors should weigh cost control progress against profitability challenges for upside.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →